Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
4.750
-0.020 (-0.42%)
Sep 9, 2024, 4:00 PM EDT - Market closed
Lifecore Biomedical Revenue
In the fiscal year ending May 26, 2024, Lifecore Biomedical had annual revenue of $128.26M with 24.20% growth. Lifecore Biomedical had revenue of $37.89M in the quarter ending May 26, 2024.
Revenue (ttm)
$128.26M
Revenue Growth
+24.20%
P/S Ratio
1.13
Revenue / Employee
$279,436
Employees
459
Market Cap
146.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | Pro | Pro | Pro |
| May 27, 2018 | Pro | Pro | Pro |
| May 28, 2017 | Pro | Pro | Pro |
| May 29, 2016 | Pro | Pro | Pro |
| May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Electromed | 54.72M |
| Fennec Pharmaceuticals | 48.89M |
| Elutia | 24.99M |
| TriSalus Life Sciences | 24.74M |
| ProQR Therapeutics | 16.90M |
| Generation Bio Co. | 13.17M |
| Sangamo Therapeutics | 12.28M |
| Seres Therapeutics | 374.00K |
LFCR News
- 13 hours ago - Lifecore Biomedical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 27, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewsWire
- 20 hours ago - Lifecore Biomedical, Inc. Is Being Sued For Possibly Violating Securities Laws And Shareholders Are Invited To Contact The Schall Law Firm - Accesswire
- 3 days ago - Lifecore Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Lifecore Biomedical, Inc. May Have Committed Securities Related Infractions And Impacted Shareholders Are Invited To Contact The Schall Law Firm - Accesswire
- 4 days ago - Lifecore Biomedical to Participate in 17th Annual Barrington Research Virtual Fall Investment Conference - GlobeNewsWire
- 4 days ago - The Schall Law Firm Seeks Investor Participation In A Lawsuit Against Lifecore Biomedical Inc For Securities Fraud - Accesswire
- 6 days ago - Lifecore Biomedical Inc. May Have Committed Securities Related Improprieties And Shareholders Are Urged To Contact The Schall Law Firm About A Case - Accesswire
- 7 days ago - The Schall Law Firm Wants Lifecore Biomedical Inc Investors To Play A Part In A Lawsuit For Securities Law Infractions - Accesswire